ORAL TOFACITINIB IN MODERATE AND SEVERE ALOPECIA AREATA: CASE SERIES OF 14 PATIENTS

Abstract

Background: Alopecia areata is an autoimmune disease that causes transient, non-scarring hair loss while maintaining the hair follicle. Tofacitinib citrate, a Janus kinase 1/3 inhibitor, has lately been used to treat alopecia areata in addition to rheumatoid arthritis (AA). We present the results of prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe AA. All patients with AA, AT, or AU assessed at a tertiary care center clinic Materials and methods: had their records located between December 2021 and December 2022. The inclusion criteria was patients must be at least 18 years old, have a clinical diagnosis of AA, AT, or AU (defined as scalp hair loss of >90%), and have had a stable or deteriorating condition for at least six months. Each patient's clinical and demographic data, including age, gender, age at disease beginning, length of the current episode of disease, and severity of AA as determined by the Severity of Alopecia Tool (SALT), were collected. The average age of the present sample was 32.24 years. Majorit Results: y of them were males (71.43%). The re-growth rate among the present study was 64.29%. The re-growth rate correlated positively with age at onset of first episode[r=0.32; 0.031] and tofacitinib duration [r=0.55; 0.004] and correlated negatively with duration of current episode [r=-0.41; 0.022] and duration of disease since first onset [r=-0.42; 0.024]. More Conclusions: than ½ of the cases we studied had good regrowth rate in the present study. The re-growth rate correlated positively with age at onset of first episode and tofacitinib duration and correlated negatively with duration of current episode and duration of disease since first onset